ARTICLE | Analyst Picks & Changes
Analyst picks & changes
December 19, 1994 8:00 AM UTC
Barbara Hoffman of Piper Jaffray said she wasn't impressed with results of Genentech Inc.'s Phase II trial of the anti-Her2 antibody in refractory breast cancer (see Clinical Results, B6). Although the drug was reported safe, with no antibody reaction, the five complete or partial responses out of 44 evaluable patients weren't impressive, she said, since placebo response rates are often in the 10-15 percent range. ...